Analysts See Long-Term Gains From Takeda-Millennium Merger
This article was originally published in PharmAsia News
Although Takeda Pharmaceutical's takeover bid for Millennium Pharmaceuticals, a U.S. biotech, caused concerns among investors, other analysts see the move as good for the Japanese firm in the long run. The $8.8 billion offer, open to shareholders into May, would position Takeda to outpace other drug makers in the cancer-drug end of the business. The purchase also is seen as protection against revenue losses expected within the next three years as Takeda patents expire on some of its best-selling drugs. Analysts even believe that despite the immediate drain a merger would have on Takeda coffers, investors would benefit from the merger in the long run. (Click here for more - a subscription may be required
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.